Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Shoko Isoyama
First-Line Immune Checkpoint Therapy in Metastatic Squamous Cell Lung Cancer Harboring Both EGFR Mutation and High Expression of PD-L1: A Case Report
Thoracic Cancer
Medicine
Pulmonary
Respiratory Medicine
Oncology
Related publications
P3.17-14 a Case of a Patient Harboring an EGFR -T790m Mutation Positive in Squamous Cell Lung Cancer
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Clinical Outcome of Treatment of Metastatic Non-Small Cell Lung Cancer in Patients Harboring Uncommon EGFR Mutation
BMC Cancer
Cancer Research
Oncology
Genetics
Effectiveness of First-Line Treatments in Metastatic Squamous Non-Small-Cell Lung Cancer
Current Oncology
Oncology
P2.01-90 PD-L1 Expression as a Predictive Biomarker in Advanced Non-Small Cell Lung Cancer Patients With or Without EGFR Mutation
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P1.01-77 Osimertinib in the First-Line Treatment of Non-Small Cell Lung Cancer Harboring Activating EGFR Mutation From Circulating Tumor DNA
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Breast Care
Surgery
Oncology
P3.13-30 Driver Mutation in Heavy Smoker Patient With Squamous Cell Carcinoma Metastatic Lung Cancer: Case Report
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
MA15.01 Strong PD-L1 Expression Predicts Poor Response and De Novo Resistance to EGFR TKIs Among Non-Small Cell Lung Cancer Patients With EGFR Mutation
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Gefitinib for a Poor Performance Status Patient With Squamous Cell Carcinoma of the Lung Harboring EGFR Mutation
Internal Medicine
Internal Medicine
Medicine
